Pro správné zobrazení obsahu stránek je potřeba povolit JavaScript nebo použít jiný webový prohlížeč

       

Chystáte se opustit stránky společnosti GSK

Chystáte se opustit stránky společnosti GSK. Kliknutím na tento odkaz budete přesměrováni na webovou stránku, která není vlastněna a spravována společností GSK a společnost GSK nenese za její obsah odpovědnost.

Pokračovat

Jít zpět

Month Names:Leden,Únor,Březen,Duben,Květen,Červen,Červenec,Srpen,Září,Říjen,Listopad,Prosinec

Month Names Short:led.,úno.,bře.,duben.,květen.,čvn.,čvc.,srp.,zář.,říj.,lis.,pro.

Day Names:pondělí,úterý,středa,čtvrtek,pátek,sobota,neděle

Day Names Short:Po,Út,St,Čt,Pá,So,Ne

Day Names Min:Po,Út,St,Čt,Pá,So,Ne

Date Format:dd.mm.yyyy

Events Filter Date Placeholder:dd.mm.yyyy

Popup

Three effective molecules in a single daily inhalation – help lessen the impact of COPD in appropriate patients. [1],[2]

By combining ICS/LAMA/LABA, TRELEGY Ellipta OD offers proven efficacy vs. BUD/FOR Turbuhaler BD, and a simple medication routine. [1],[2]

See Efficacy data

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. [1]

Breathlessness

Improves lung function

Help appropriate patients with COPD breathe easier vs. BUD/FOR Turbuhaler BD. 2

See data in breathlessness

Quality of life

Improves health-related quality of life

Help appropriate patients with COPD improve their health status vs. BUD/FOR Turbuhaler BD. 2

Explore the impact on health status

Exacerbations

Improve COPD symptom control

Help appropriate patients with COPD improve symptoms and so reduce exacerbation risk vs. BUD/FOR Turbuhaler BD. 2

View exacerbation outcomes

Register today

Receive the latest information about TRELEGY Ellipta.

Sign up here

BD, twice-daily; BUD, budesonide; COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroids; LABA, long-acting β₂-agonist; LAMA, long acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol

References:

  1. TRELEGY Ellipta Summary of Product Characteristics, 2017. 
  2. Lipson DA et al. Am J Respir Crit Care Med. 2017; 196(4): 438-446.


TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.

Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution